Caring Cross

?? Simplifying CAR-T workflows will help to break down barriers to patient access Tune into our new episode of the Ori Spotlight Podcast, where Boro Dropuli??, CEO of Vector BioMed, Inc. and Executive Director at Caring Cross, joins Ori CEO Jason C. Foster for a conversation on how decentralized, point-of-care models and open-source workflows are transforming CGT manufacturing. Boro and Jason discuss how low-cost vector production and new manufacturing processes are key to expanding global access to CAR-T therapies, and delve into the role of digital technologies and partnerships in driving down the costs of gene therapies while maintaining GMP quality. Listen now ?? https://lnkd.in/eZdT6krq #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

This month, the sector has seen some notable developments in Brazil. The country granted marketing authorization to Upstaza, a gene therapy developed by PTC Therapeutics, Inc. to treat AADC deficiency. This is the third gene therapy product approved in Brazil, with Novartis’ Zolgensma and Spark Therapeutics, Inc.'s Luxturna both approved in 2020. https://lnkd.in/eE-kvhfE Additionally, GEMMA Biotherapeutics announced last week that it reached a $100 million agreement with Brazil’s Fiocruz, a public health research institute, to develop and manufacture cell and gene therapies for rare diseases. https://lnkd.in/eMH2ynNJ These are encouraging developments for advancing global access to cell and gene therapies beyond regions like North America, Europe, and East Asia.

I recently had the opportunity to interview Dr. Boro Dropuli?, Executive Director of Caring Cross, on how they are reshaping the future of CAR-T cell therapies through their decentralized manufacturing model. With the global cancer burden continuing to rise and treatment costs exceeding $350,000, Caring Cross is making groundbreaking strides in reducing therapy prices to as low as $35,000. Their mission? To bring affordable, life-saving treatments to patients worldwide, especially in low- and middle-income countries. It’s inspiring to see how nonprofits like Caring Cross are driving healthcare equity, one innovative step at a time. Read the full interview to learn more about how Dr. Dropuli? and his team are making this possible: #CAR_TCellTherapy #HealthcareEquity #CancerTreatment #CaringCross #GlobalHealth #DecentralizedManufacturing? BioSpectrum Asia